Workshops seek to give nurses tools to translate medtech ideas into reality.
Health Care + Med Tech
The state placed sixth in an annual report from the United Health Foundation.
The sticking point is whether Mayo would then gain the ability to make changes to the benefits packages unilaterally, be they additions or subtractions to the current plans.
Encountering a foreign-born doctor in Greater Minnesota once might have been unusual. If the state’s health-care trends continue as they have, it won’t be much longer.
ZOLL Medical Corporation, a medical device and software firm owned by the Japanese chemical company Asahi Kasei, led the funding round.
Study suggests patients influenced more by providers than potential out-of-pocket costs.
The deal came as Rochester laundry was purchased by Wisconsin company.
If the bill were passed with its current language, medtech companies—many of which call Minnesota home—will avoid the 2.3 excise tax until 2023.
Through the purchase, Medtronic will acquire products that provide doctors with an internal view of the esophagus during endoscopic and surgical procedures.
The deal remains contingent on Entellus shareholder approval, as well as regulatory approval.
State study projects a nearly 35 percent increase with employers likely picking up much of the tab.
Fundraising comes after positive pre-clinical results for its AnestaGel product.
Using OptumLab data, researchers found some anticoagulants are easier on kidneys.
The deal has widely been compared to CVS’s proposed merger with Atena—since both cases involve the increasingly blurred lines in the healthcare industry—as insurance companies become more involved in direct care.
The study’s lead researcher, Michael McAlpine, said the discovery could be a “game-changer” and lead to fewer medical errors during surgery.
On-site and near-site clinics, along with wellness programs, are producing good results for employees of Minnesota companies.
Edina, St. Louis Park and Bloomington passed similar ordinances earlier this year.
The new collaboration is seeking to develop a ‘microbiome’ drug for multiple sclerosis and rheumatoid arthritis.